CoChat

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Open access
Pignon, Jean-Christophe, Jegede, Opeyemi, Shukla, Sachet A., Braun, David A., Horak, Christine E., Wind-Rotolo, Megan, Ishii, Yuko, Catalano, Paul J., Grosha, Jonian, Flaifel, Abdallah, Novak, Jesse S., Mahoney, Kathleen M., Freeman, Gordon J., Sharpe, Arlene H., Hodi, F. Stephen, Motzer, Robert J., Choueiri, Toni K., Wu, Catherine J., Atkins, Michael B., McDermott, David F., Signoretti, Sabina · 2019 · Clinical Cancer Research
Cited by 113

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: Immune-related RECIST (irRECIST) were designed to capture atypical responses seen with immunotherapy. We hypothesized that, in patients with metastatic clear cell renal cell carcinoma (mccRCC), candidate biomarkers for nivolumab response would show improved association with clinical endpoints capturing atypical responders (irRECIST) compared with standard clinical endpoints (RECISTv1.1). Experimental Design: Endpoints based on RECISTv1.1 [objective response rate (ORR)/progression-free survival (PFS)] or irRECIST [immune-related ORR (irORR)/immune-related PFS (irPFS)] were compared in patients enrolled in the CheckMate-010 trial. Pretreatment tumors were analyzed by PD-L1 and PD-L2 IHC, and by multiplex immunofluorescence for CD8, PD-1, TIM-3, and LAG-3. T-cell activation signatures were assessed by RNA sequencing. Results: Median irPFS was significantly longer than median PFS. irORR was not significantly different from ORR, but immune-related progressive disease (irPD) rate was significantly lower than progressive disease (PD) rate. Tumor cell (TC) PD-L1 expression was not associated with PFS or ORR, but patients with TC PD-L1 ≥1% had longer median irPFS and higher irORR. High percentage of CD8+ tumor-infiltrating cells (TIC) that are PD-1+TIM-3−LAG-3− (% CD8+PD-1+TIM-3−LAG-3− TIC) correlated with high levels of T-cell activation and was associated with longer median irPFS and higher irORR. Notably, combination of TC PD-L1 expression with % CD8+PD-1+TIM-3−LAG-3− TIC identified three groups of patients for which irPFS and irORR were significantly different. Conclusions: Atypical responders to nivolumab were identified in the CheckMate-010 trial. We observed improved association of candidate biomarkers for nivolumab response with endpoints defined by irRECIST compared with RECISTv1.1. TC PD-L1 expression in combination with PD-1 expression on CD8+ TIC may predict outcome on nivolumab in mccRCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3206

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 113

Metadata

Authors
Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., Novak, J. S., Mahoney, K. M., Freeman, G. J., Sharpe, A. H., Hodi, F. S., Motzer, R. J., Choueiri, T. K., Wu, C. J., Atkins, M. B., McDermott, D. F., & Signoretti, S.
Venue
Clinical Cancer Research
Published
2019-04-01
Volume
25
Issue
7
Pages
2174-2184
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2913044136
Cited by
113
References
9
FWCI
5.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3206
The paper
Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., Novak, J. S., Mahoney, K. M., Freeman, G. J., Sharpe, A. H., Hodi, F. S., Motzer, R. J., Choueiri, T. K., Wu, C. J., Atkins, M. B., . . . Signoretti, S. (2019). irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3206

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.